US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Binah Capital Group Inc

2.01

+0.05002.55%

Volume:12.67K

Turnover:25.28K

Market Cap:33.37M

PE:-6.28

High:2.03

Open:1.88

Low:1.88

Close:1.96

Loading ...

Overview Company News Filings

Why FTI Consulting (FCN) Is Among the Best Consulting Stocks to Buy Right Now?

Why Forrester Research (FORR) Is Among the Best Consulting Stocks to Buy Right Now?

1 Stock-Split AI Stock to Buy Before It Soars 450%, According to a Wall Street Expert

TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy

CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

How hard it is to get hired and what it's like to work for the prestigious strategy consulting firms, McKinsey, Bain, and BCG

businessinsider.com

enGene to Participate in Upcoming Investor Conferences

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

BRIEF-ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial

Global Boards Show Progress in Sustainability, But AI and Geopolitical Risks Loom Large, Reports Heidrick & Struggles

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Press Release: CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCG/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","market":"US","secType":"STK","nameCN":"Binah Capital Group Inc","latestPrice":2.01,"timestamp":1743702370170,"preClose":1.96,"halted":0,"volume":12672,"delay":0,"floatShares":4546841,"shares":16602460,"eps":-0.32,"marketStatus":"Trading","change":0.05,"latestTime":"04-03 14:28:53 EDT","open":1.88,"high":2.03,"low":1.88,"amount":25279.872076800002,"amplitude":0.076531,"askPrice":2.03,"askSize":200,"bidPrice":1.99,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.32,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743710400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.96,"preHourTrading":{"tag":"盘前","latestPrice":1.88,"preClose":1.96,"latestTime":"08:00 EDT","volume":23,"amount":43.1099994,"timestamp":1743681600178},"postHourTrading":{"tag":"盘后","latestPrice":1.96,"preClose":1.96,"latestTime":"19:16 EDT","volume":5,"amount":9.6,"timestamp":1743635768762},"volumeRatio":0.574037},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","floatShares":4546841,"roa":"-6.80%","roe":"-42.87%","lyrEps":-0.274935,"volumeRatio":0.574037,"shares":16602460,"dividePrice":0,"high":2.03,"amplitude":0.076531,"preClose":1.96,"low":1.88,"week52Low":1.71,"pbRate":"-124.06","psRate":"0.20","week52High":12.22,"institutionHeld":0,"latestPrice":2.01,"committee":-0.333333,"eps":-0.32,"divideRate":0,"volume":12672,"delay":0,"ttmEps":-0.32,"open":1.88,"prevYearClose":2.94,"prevWeekClose":1.95,"prevMonthClose":1.93,"prevQuarterClose":1.93,"fiveDayClose":2.01,"twentyDayClose":2.24,"sixtyDayClose":2.79},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCG\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2491662305","title":"Why FTI Consulting (FCN) Is Among the Best Consulting Stocks to Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491662305","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491662305?lang=en_us&edition=fundamental","pubTime":"2024-12-14 01:20","pubTimestamp":1734110440,"startTime":"0","endTime":"0","summary":"We recently published a list of 11 Best Consulting Stocks to Buy Right Now. In this article, we are going to look at where FTI Consulting, Inc.  stands against other best consulting stocks to buy right now.According to a report by Mordor Intelligence, the Consulting Service Market is valued at $354.01 billion in 2024 and is projected to reach $447.72 billion by 2029, growing at a Compound Annual Growth Rate  of 4.81%. This growth is driven by several key factors, including the increasing complexity of business operations, the rapid evolution of technology landscapes, and a heightened focus on strategic decision-making. The integration of technology into consulting services is a significant trend shaping the market. Technology-driven consulting leverages advanced tools and techniques to offer cutting-edge solutions.Big Consulting Firms Profit Massively from AI Consulting. To compile our list of the 11 best consulting stocks to buy right now, we used","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rHRPR1M86GwrsvUUqoV6Qg--~B/aD02NjQ7dz0xMDgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/96afc090bacb1351363751f049f11480","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rHRPR1M86GwrsvUUqoV6Qg--~B/aD02NjQ7dz0xMDgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/96afc090bacb1351363751f049f11480"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-fti-consulting-fcn-among-172040865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCG","LU1878469433.USD","BK4159","FTI","LU0300736062.USD","BK4123","LU0053671581.USD","LU0300736492.USD","BK4179","IE00B64QTZ34.USD","BK4135","LU0054578231.USD","CAGR","FCN"],"gpt_icon":0},{"id":"2491305979","title":"Why Forrester Research (FORR) Is Among the Best Consulting Stocks to Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491305979","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491305979?lang=en_us&edition=fundamental","pubTime":"2024-12-14 01:15","pubTimestamp":1734110116,"startTime":"0","endTime":"0","summary":"We recently published a list of 11 Best Consulting Stocks to Buy Right Now. In this article, we are going to look at where Forrester Research, Inc.  stands against other best consulting stocks to buy right now.According to a report by Mordor Intelligence, the Consulting Service Market is valued at $354.01 billion in 2024 and is projected to reach $447.72 billion by 2029, growing at a Compound Annual Growth Rate  of 4.81%. This growth is driven by several key factors, including the increasing complexity of business operations, the rapid evolution of technology landscapes, and a heightened focus on strategic decision-making. The integration of technology into consulting services is a significant trend shaping the market. Technology-driven consulting leverages advanced tools and techniques to offer cutting-edge solutions.The consulting service market is on the cusp of substantial growth, fueled by the increasing complexity of business operations, the rapid pace of technological evolution,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GFVbb9MOaflTT5QAU8MZ2w--~B/aD02Mjg7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a8a2c0568951faf5c11e5b9060228295","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GFVbb9MOaflTT5QAU8MZ2w--~B/aD02Mjg7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a8a2c0568951faf5c11e5b9060228295"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-forrester-research-forr-among-171516875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","QLD","TQQQ","USAW.SI","TSYW.SI",".IXIC","BK4135","MNQmain","SQQQ","FORR","BK4123","USJW.SI","BK4159","BCG","IE00B19Z6F94.USD","PSQ","NVIW.SI","CAGR","QID"],"gpt_icon":1},{"id":"2489478459","title":"1 Stock-Split AI Stock to Buy Before It Soars 450%, According to a Wall Street Expert","url":"https://stock-news.laohu8.com/highlight/detail?id=2489478459","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489478459?lang=en_us&edition=fundamental","pubTime":"2024-12-08 15:45","pubTimestamp":1733643900,"startTime":"0","endTime":"0","summary":"Phil Panaro believes Nvidia's dominance in artificial intelligence  accelerators will carry the stock to $800 per share by 2030.Nvidia has a key advantage in vertical integration, which lets it build data center systems with a superior total cost of ownership.Nvidia shares have returned more than 900% since late 2022, but the stock still trades at a reasonable valuation in context.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800178%2Fartificial-intelligence-12.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800178%2Fartificial-intelligence-12.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/08/1-stock-split-ai-stock-buy-before-soars-450-wall/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["NVDY","2NVD.UK","NVD3.UK","LU2242650005.HKD","IE00BQXX3C00.GBP","SNVD.UK","IE00BDRTCR15.USD","LU0683600562.USD","NVDS","LU2756315318.SGD","LU1935042488.USD","LU1629891620.HKD","PEG","LU1267930490.SGD","LU2087625088.SGD","NVDA","LU2264538146.SGD","LU2237957902.USD","LU0823434740.USD","LU0648000940.SGD","LU1261432733.SGD","IE00BDCRKT87.USD","NVD","IE00BSNM7G36.USD","LU2087621335.USD","SG9999014575.USD","BK4573","NVDX","LU0251131958.USD","LU0251132253.USD","LU0267386448.USD","LU2265009873.SGD","NVD2.UK","BK4527","LU2756315664.SGD","3NVD.UK","NVDS.UK","LU1633808545.USD","LU0029864427.USD","LU1814569148.SGD","LU0211327993.USD","IE00BKPKM429.USD","BCG","LU1506573853.SGD","NVDD","LU1035775433.USD","NVDU","LU0077335932.USD"],"gpt_icon":1},{"id":"2489615258","title":"TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2489615258","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489615258?lang=en_us&edition=fundamental","pubTime":"2024-12-06 22:34","pubTimestamp":1733495640,"startTime":"0","endTime":"0","summary":"Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the pre-planned interim analysis of its ongoing mid-stage study evaluating intravesical TARA-002 for treating non-muscle invasive bladder cancer .TARA-002 is Protara’s investigational cell therapy, which is currently in development for treating NMIBC and lymphatic malformations . The candidate enjoys the FDA’s Rare Pediatric Disease designation for treating these indications in the United States.NMIBC patients treated with TARA-002 achieved a complete response  rate of 72% at six months and 70% at any time across BCG exposures with 100% of patients maintaining a CR from three months to six months. Protara also reported that two out of three treated patients maintained a CR at nine months.In the past three months, shares of TARA have skyrocketed 227.2% against the industry’s 7.3% decline.Apart from TARA-002, Protara’s clinical pipeline comprises an investigational IV phosphol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tara-stock-soars-superior-efficacy-143400446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087621335.USD","LU1894683348.USD","IE00BLSP4452.SGD","BCG","SGXZ57979304.SGD","LU1057294990.SGD","SG9999002224.SGD","TARA","LU0122379950.USD","IE00B19Z3B42.SGD","BK4534","LU0234570918.USD","IE00B19Z3581.USD","IE00BKVL7J92.USD","BK4161","IE00BZ1G4Q59.USD","LU0868494617.USD","CR","BK4599","SG9999013999.USD","LU0306807586.USD","LU0889565916.HKD","LU0170899867.USD","LU2468319806.SGD","BK4007","BK4585","SG9999002232.USD","BK4532","BK4139","IE00B3T34201.USD","LU0225771236.USD","BK4548","PFE","LU1883839398.USD","GILD","LU0058720904.USD","BK4588","ALNY","LU0234572021.USD","LU0320765992.SGD","LU0985481810.HKD","LU1839511570.USD","LU1066053197.SGD","LU0321505868.SGD","LU0321505439.SGD","BK4566","LU1066051498.USD","LU0306806265.USD","BK4550","SG9999003800.SGD"],"gpt_icon":1},{"id":"2489605467","title":"CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2489605467","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489605467?lang=en_us&edition=fundamental","pubTime":"2024-12-06 00:35","pubTimestamp":1733416538,"startTime":"0","endTime":"0","summary":"On Thursday, CG Oncology, Inc.  revealed topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer  unresponsive to Bacillus Calmette Guerin .The trial demonstrated that 74.5% of patients  achieved a complete response  at any time after receiving treatment with cretostimogene as a single agent.The median duration of response  has not been reached but exceeds 27 months as of the data cutoff of September 30.Gary Steinberg, Professor, Department of Urology at Rush University Medical Center, said, “I am very encouraged by the latest data from the BOND-003 study, which demonstrates cretostimogene’s compelling efficacy as well as its potential to induce a best-in-class durable response in NMIBC patients, with 63.5% of patients remaining in response at 12 months or greater and 56.6% of patients remaining in response at 24 months or greater, by K-M estimate. Additionally, 97.3% of patients were free from progression to Muscle Invasive Bladder Ca","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HEWmOk2Oa.dWxKly0Ikk.w--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a919db55789307d3b71f71634a9d2cbd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HEWmOk2Oa.dWxKly0Ikk.w--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a919db55789307d3b71f71634a9d2cbd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-touts-encouraging-data-163538076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BCG","SSI","BK4139","CR","IE00BGHQF748.EUR","BK4135","IE00B64PRP62.GBP","CGON","CG","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2489430673","title":"Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489430673","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489430673?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400000,"startTime":"0","endTime":"0","summary":"– 74.5% of patients achieved a complete response at any time –。– Median duration of response is greater than 27 months and not reached –。– Latest data update continued to show favorable safety and tolerability results –。– Company hosting virtual investor event with lead investigator at 8 am EST today –。There were no Grade 3 or greater treatment-related adverse events  or deaths reported. No treatment-related discontinuation of cretostimogene was observed. 97.3% of patients completed all expected treatments, demonstrating favorable patient adherence and compliance. The most common TRAEs  were bladder spasm, pollakiuria, micturition urgency, dysuria, and hematuria.“The BOND-003 monotherapy data underscores our novel investigational oncolytic immunotherapy’s unique product profile, including its dual mechanism of action, which we believe differentiates it from current and investigational NMIBC treatments,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “Based upon t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/groundbreaking-cretostimogene-grenadenorepvec-monotherapy-data-120000639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","BCG","BK4139","BK4161","CGON","BK4135"],"gpt_icon":0},{"id":"2489430081","title":"Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2489430081","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489430081?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400000,"startTime":"0","endTime":"0","summary":"TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete respo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/05/2992222/0/en/Protara-Announces-Positive-Results-from-the-Ongoing-Phase-2-ADVANCED-2-Trial-of-TARA-002-in-Patients-with-NMIBC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BCG","IE00B7SZL793.SGD","IFN","IE00B66KJ199.SGD","IE00B19Z4B17.USD","TARA","AEIS","IE0031619046.USD","CR","BK4135","BK4139","BK4523","BK4157"],"gpt_icon":0},{"id":"2488914094","title":"Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488914094","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488914094?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:00","pubTimestamp":1733230800,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2024  (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990535/0/en/Protara-Therapeutics-to-Host-Conference-Call-and-Webcast-to-Review-New-Interim-Data-from-Phase-2-ADVANCED-2-Trial-of-TARA-002-in-Patients-with-NMIBC-on-Thursday-December-5-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","BK4218","IFN","BK4157","BK4523","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4585","BK4139","BK4588","IE0031619046.USD","IE00B7SZL793.SGD","BK4135","BCG","TARA","BK4181","HST"],"gpt_icon":0},{"id":"2487552561","title":"How hard it is to get hired and what it's like to work for the prestigious strategy consulting firms, McKinsey, Bain, and BCG","url":"https://stock-news.laohu8.com/highlight/detail?id=2487552561","media":"businessinsider.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487552561?lang=en_us&edition=fundamental","pubTime":"2024-11-29 20:04","pubTimestamp":1732881842,"startTime":"0","endTime":"0","summary":"McKinsey, Bain, and BCG are top strategy consulting firms with low acceptance rates.These firms, known as MBB, serve Fortune 500 companies and offer competitive salaries.MBB firms provide prestigious ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businessinsider.com/mbb-explained-mckinsey-bain-bcg-compare-big-three-strategy-consultants-2024-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"businsider_highlight","symbols":["BK4135","BCG"],"gpt_icon":0},{"id":"2486081885","title":"enGene to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2486081885","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486081885?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:00","pubTimestamp":1732539600,"startTime":"0","endTime":"0","summary":"BOSTON & MONTREAL, November 25, 2024----enGene Holdings Inc. , a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid  is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin -unresponsive, non-muscle invasive bladder cancer  with carcinoma in situ , today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will participate in upcoming investor conferences. Details of the conferences are below:. Conference: Virtual Citizens JMP Hematology & Oncology SummitDate: Monday, December 2, 2024Time: 10:00 a.m. ETFormat: Corporate Presentation. Conference: Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Time: 3:00 p.m. ETFormat: Fireside Chat. A live webcast of these presentations can be accessed under the \"Investors\" section of the enGene website at www.engene.com and will be archived there for 90 days.For media contact: media@engene.com For investor contact","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jMxGjRIscFqrzCbNr_8h3g--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/98365657a4df37c1c37dcc5324085176","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jMxGjRIscFqrzCbNr_8h3g--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/98365657a4df37c1c37dcc5324085176"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/engene-participate-upcoming-investor-conferences-130000658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENGNW","ENGN","BCG","BK4135"],"gpt_icon":0},{"id":"2485284207","title":"Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds","url":"https://stock-news.laohu8.com/highlight/detail?id=2485284207","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485284207?lang=en_us&edition=fundamental","pubTime":"2024-11-23 23:24","pubTimestamp":1732375446,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds.In this article, we are going to take a look at where Immunitybio Inc.  stands against the other promising cancer stocks.According to the World Health Organization , cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide. Moreover, the World Cancer Research Fund reports that approximately 18.1 million cancer cases were diagnosed that year, with the age-standardized rate, when considering all cancers except non-melanoma skin cancer and combining data for both men and women, came in at 190 cases per 100,000 individuals. This rate was notably higher in men, with 206.9 cases per 100,000, compared to 178.1 per 100,000 in women.Since there is no universal cure for cancer, developing a drug capable of treating multiple cancer types is incredibly lucrative. This dynamic fuels continuous breakthroughs in the oncol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IK2NRTKYd4JDOTMuljjZjA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/500e6a9b9446270927386ff74e5c8c2b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IK2NRTKYd4JDOTMuljjZjA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/500e6a9b9446270927386ff74e5c8c2b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-inc-ibrx-among-most-152406572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","MNQmain","NQmain","BCG","BK4135","CAGR","BK4159","SQQQ",".IXIC","BK4139","QID","IBRX","TQQQ","QLD"],"gpt_icon":1},{"id":"2484115884","title":"CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2484115884","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484115884?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:00","pubTimestamp":1732107600,"startTime":"0","endTime":"0","summary":"Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress PostersIRVINE, Calif., Nov.  20, 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/20/2984393/0/en/CG-Oncology-to-Present-Results-on-Cretostimogene-Grenadenorepvec-at-the-Society-of-Urologic-Oncology-SUO-25th-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","CGON","CG","BK4135","IE00BGHQF748.EUR","BCG"],"gpt_icon":1},{"id":"2484941840","title":"BRIEF-ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484941840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484941840?lang=en_us&edition=fundamental","pubTime":"2024-11-19 21:22","pubTimestamp":1732022540,"startTime":"0","endTime":"0","summary":"Nov 19  - Immunitybio Inc   :   * IMMUNITYBIO COMPLETES ANKTIVA’S POST-APPROVAL ENROLLMENT OF THE 100TH PATIENT IN BCG UNRESPONSIVE NMIBC CIS TRIAL AND REPORTS A COMPLETE RESPONSE RATE OF 71% WITH A DURABLE DURATION OF RESPONSE RANGING UP TO 54 MONTHS   * IMMUNITYBIO INC - DATA TO BE SUBMITTED TO EMA IN Q4 2024Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4212","BCG","BK4139","BK4135","POST"],"gpt_icon":0},{"id":"2484913720","title":"Global Boards Show Progress in Sustainability, But AI and Geopolitical Risks Loom Large, Reports Heidrick & Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2484913720","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484913720?lang=en_us&edition=fundamental","pubTime":"2024-11-19 18:00","pubTimestamp":1732010400,"startTime":"0","endTime":"0","summary":"New global survey by Heidrick & Struggles, BCG, and INSEAD, reveals growing confidence in sustainability governance, but boards and CEOs still lack confidence in each other's leadership. LONDON, Nov. 19, 2024 /PRNewswire/ -- Heidrick & Struggles, a premier provider of global leadership advisory and on-demand talent solutions, has teamed with Boston Consulting Group and the INSEAD Corporate Governance Centre, to publish a report exploring how boards are responding to complex trends and disruptions they currently face. Boards and Society: How Boards Are Evolving to Meet Challenges from Sustainability to Geopolitical Volatilityreveals boards have made meaningful advances to address sustainability topics, but are less confident when it comes to their understanding of other issues such as the rising importance of generative AI, intensifying trade and geopolitical disruptions. These four interconnected pillars are forcing directors and CEOs to navigate an increasingly unpredictable environme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/global-boards-show-progress-sustainability-100000489.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/global-boards-show-progress-sustainability-100000489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065732104.USD","BK4130","BCG","BK4097","BK4135","PRGS","HSII"],"gpt_icon":0},{"id":"2483349305","title":"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2483349305","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483349305?lang=en_us&edition=fundamental","pubTime":"2024-11-16 06:52","pubTimestamp":1731711120,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  15, 2024  (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/15/2982285/0/en/Protara-Therapeutics-to-Present-New-Interim-Data-from-Phase-2-ADVANCED-2-Trial-of-TARA-002-in-Patients-with-NMIBC-at-the-25th-Annual-Meeting-of-the-Society-of-Urologic-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFN","BCG","BK4135","IE00B7SZL793.SGD","AEIS","BK4523","IE00B66KJ199.SGD","IE0031619046.USD","IE00B19Z4B17.USD","BK4139","TARA","BK4157"],"gpt_icon":0},{"id":"2482709266","title":"Press Release: CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2482709266","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482709266?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology  25th Annual Meeting -. IRVINE, Calif., Nov. 12, 2024  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quarter ended September 30, 2024, and provided business updates.\"This quarter, we've continued to make significant advancements across our pipeline to bring forward a potential backbone bladder-sparing therapy for patients with Non-Muscle Invasive Bladder Cancer ,\" said Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology. \"As we reported earlier this year at the AUA and ASCO annual meetings, cretostimogene has the ability to induce a sustained and durable complete response in bladder cancer patients with a strong safety an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","IE00BGHQF748.EUR","BK4135","BCG","BK4139","IE00B64PRP62.GBP","CG","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2482013317","title":"Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482013317","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482013317?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979056/0/en/Protara-Therapeutics-Announces-Third-Quarter-2024-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","IFN","BK4523","BK4139","BCG","LENZ"],"gpt_icon":0},{"id":"2482786051","title":"CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2482786051","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482786051?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 –。– Encouraging data adds to the body of evidence supporting potential use of cretostimogene as a backbone bladder-sparing therapeutic for bladder cancer –。This is the second publication in Nature Medicine evaluating the safety and efficacy of cretostimogene grenadenorepvec this year. In June 2024, Nature Medicine published the final results from CORE-001, a phase 2 study of cretostimogene grenadenorepvec in combination with another checkpoint inhibitor, pembrolizumab, in high-risk Bacillus Calmette Guerin -unresponsive non-muscle invasive bladder cancer .About the Phase 1b StudyThe Phase 1b study examined the safety and efficacy of combining cretostimogene grenadenorepvec with nivolumab in patients with MIBC who were ineligible for cisplatin chemotherapy. Of the 21 patients enrolled and treated, there were no dose-limiting toxicity and no grade 3 or h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-announces-nature-medicine-130000011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","BK4080","BCG","CGON","TRAE","BK4139","IE00BGHQF748.EUR","BK4231","BK4135","CG","SITC","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2481606068","title":"Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481606068","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481606068?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898000,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  06, 2024  (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2975648/0/en/Protara-Therapeutics-to-Present-at-the-Guggenheim-Inaugural-Healthcare-Innovation-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","BCG","BK4137","LENZ","HCSG"],"gpt_icon":0},{"id":"2481506284","title":"enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481506284","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481506284?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"BOSTON & MONTREAL, November 05, 2024----enGene Holdings Inc. , a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid  is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin -unresponsive, non-muscle invasive bladder cancer  with carcinoma in situ , today announced that Ron Cooper, Chief Executive Officer, and Raj Pruthi, M.D., Chief Medical Officer, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 10:30 a.m. ET.A live webcast of the fireside chat can be accessed under the \"Investors\" section of the enGene website at www.engene.com and will be archived there for 90 days.For media contact: media@engene.com For investor contact: investors@engene.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/G5fS1_S5wWzhASgfCvn2ZQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/3030a17bab8712f9dd7661c1f314f23d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/G5fS1_S5wWzhASgfCvn2ZQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/3030a17bab8712f9dd7661c1f314f23d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/engene-participate-guggenheim-inaugural-healthcare-130000798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","ENGN","BK4139","BCG","BK4137","HCSG","ENGNW"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":113}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCG\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCG","date":"2025-04-02","current":-7.314981,"percent":0.80786,"low":-94.684933,"twenty":-19.585275,"median":-11.033886,"eighty":-7.373772,"high":216.897522,"avg":4.462016,"sd":62.211534,"marketCap":33370944},"quantilePoints":[{"date":"2024-04-12","current":47.846282,"twenty":47.314657,"median":50.799756,"eighty":52.276493,"marketCap":133339024},{"date":"2024-04-19","current":40.132439,"twenty":41.297957,"median":46.73873,"eighty":50.917895,"marketCap":111841925},{"date":"2024-04-26","current":203.935518,"twenty":44.420253,"median":50.799756,"eighty":187.977853,"marketCap":116447181},{"date":"2024-05-03","current":181.468046,"twenty":45.542573,"median":118.644354,"eighty":199.211588,"marketCap":103618254},{"date":"2024-05-10","current":158.424485,"twenty":47.403261,"median":158.424485,"eighty":194.026786,"marketCap":90460381},{"date":"2024-05-17","current":135.380923,"twenty":48.08256,"median":150.76106,"eighty":191.347973,"marketCap":77302507},{"date":"2024-05-24","current":216.897522,"twenty":50.268131,"median":142.815352,"eighty":191.347973,"marketCap":123848485},{"date":"2024-05-31","current":-70.098677,"twenty":46.96024,"median":139.70159,"eighty":188.726768,"marketCap":145945446},{"date":"2024-06-07","current":-77.180156,"twenty":40.710114,"median":130.655552,"eighty":184.646906,"marketCap":160689084},{"date":"2024-06-14","current":-52.991736,"twenty":-57.718026,"median":121.266741,"eighty":182.34255,"marketCap":110328794},{"date":"2024-06-21","current":-39.863152,"twenty":-52.943996,"median":66.796341,"eighty":180.865278,"marketCap":82995083},{"date":"2024-06-28","current":-46.865063,"twenty":-56.142596,"median":53.605557,"eighty":179.659743,"marketCap":97573062},{"date":"2024-07-05","current":-45.194153,"twenty":-52.896255,"median":49.470693,"eighty":176.203209,"marketCap":94094226},{"date":"2024-07-12","current":-42.966272,"twenty":-51.448132,"median":45.631177,"eighty":169.370177,"marketCap":89455779},{"date":"2024-07-15","current":-46.626362,"twenty":-50.795682,"median":45.409667,"eighty":167.641909,"marketCap":97076086},{"date":"2024-08-02","current":-31.986002,"twenty":-50.143231,"median":45.188156,"eighty":165.913642,"marketCap":66594857},{"date":"2024-08-09","current":-28.166778,"twenty":-49.363473,"median":40.613835,"eighty":159.576663,"marketCap":58643232},{"date":"2024-08-16","current":-20.272151,"twenty":-47.35838,"median":-24.029285,"eighty":158.424485,"marketCap":59802844},{"date":"2024-08-23","current":-19.247598,"twenty":-46.674102,"median":-19.602159,"eighty":156.120128,"marketCap":56780413},{"date":"2024-08-30","current":-19.866672,"twenty":-46.24444,"median":-19.585275,"eighty":147.891273,"marketCap":58606683},{"date":"2024-09-06","current":-18.302664,"twenty":-45.957998,"median":-19.585275,"eighty":144.080444,"marketCap":53992860},{"date":"2024-09-13","current":-15.251751,"twenty":-45.448768,"median":-19.106899,"eighty":140.947095,"marketCap":44992666},{"date":"2024-09-20","current":-16.883858,"twenty":-45.194153,"median":-18.403405,"eighty":138.834001,"marketCap":49807380},{"date":"2024-09-27","current":-18.009448,"twenty":-45.194153,"median":-18.156337,"eighty":136.530797,"marketCap":53127872},{"date":"2024-10-04","current":-14.801515,"twenty":-45.098673,"median":-18.009448,"eighty":129.710478,"marketCap":43664469},{"date":"2024-10-11","current":-15.139192,"twenty":-44.271652,"median":-17.794742,"eighty":123.304944,"marketCap":44660617},{"date":"2024-10-18","current":-13.732204,"twenty":-43.642912,"median":-16.883858,"eighty":121.209133,"marketCap":40510002},{"date":"2024-10-25","current":-11.706141,"twenty":-43.204974,"median":-16.377341,"eighty":95.05469,"marketCap":34533116},{"date":"2024-10-31","current":-12.147373,"twenty":-41.725024,"median":-16.067805,"eighty":68.991477,"marketCap":35834749},{"date":"2024-11-08","current":-12.325216,"twenty":-38.781038,"median":-15.870826,"eighty":54.048578,"marketCap":36359387},{"date":"2024-11-15","current":-19.641554,"twenty":-35.089122,"median":-15.983385,"eighty":51.154173,"marketCap":57942585},{"date":"2024-11-22","current":-9.482521,"twenty":-31.222157,"median":-15.814546,"eighty":49.736506,"marketCap":41174100},{"date":"2024-11-29","current":-9.867391,"twenty":-29.805862,"median":-15.758267,"eighty":48.08256,"marketCap":42834346},{"date":"2024-12-06","current":-9.217214,"twenty":-28.707835,"median":-15.561288,"eighty":47.403261,"marketCap":40011928},{"date":"2024-12-13","current":-11.205991,"twenty":-28.548701,"median":-15.251751,"eighty":45.542573,"marketCap":48645207},{"date":"2024-12-20","current":-8.873003,"twenty":-28.103124,"median":-15.039858,"eighty":44.420253,"marketCap":38517707},{"date":"2024-12-27","current":-11.66494,"twenty":-27.84851,"median":-14.773376,"eighty":41.348639,"marketCap":50637503},{"date":"2025-01-03","current":-10.555814,"twenty":-27.84851,"median":-14.407558,"eighty":41.145913,"marketCap":45822789},{"date":"2025-01-10","current":-10.364586,"twenty":-27.132405,"median":-13.712083,"eighty":40.517556,"marketCap":44992666},{"date":"2025-01-17","current":-9.599672,"twenty":-25.795677,"median":-13.338247,"eighty":11.509386,"marketCap":41672174},{"date":"2025-01-24","current":-9.561426,"twenty":-24.74539,"median":-12.325216,"eighty":-7.572649,"marketCap":41506150},{"date":"2025-01-31","current":-8.069843,"twenty":-22.526431,"median":-12.059139,"eighty":-7.572649,"marketCap":35031190},{"date":"2025-02-07","current":-8.299318,"twenty":-20.109959,"median":-11.84684,"eighty":-7.649141,"marketCap":36027338},{"date":"2025-02-14","current":-7.955106,"twenty":-19.799137,"median":-11.755302,"eighty":-7.809773,"marketCap":34533116},{"date":"2025-02-21","current":-7.534404,"twenty":-19.697834,"median":-11.685541,"eighty":-7.672088,"marketCap":32706846},{"date":"2025-02-28","current":-10.976517,"twenty":-19.697834,"median":-11.593582,"eighty":-7.542053,"marketCap":47649060},{"date":"2025-03-07","current":-8.567038,"twenty":-19.686578,"median":-11.300169,"eighty":-7.572649,"marketCap":37189510},{"date":"2025-03-14","current":-7.381421,"twenty":-19.641554,"median":-11.255905,"eighty":-7.572649,"marketCap":32042747},{"date":"2025-03-21","current":-7.151947,"twenty":-19.630298,"median":-11.225114,"eighty":-7.350824,"marketCap":31046600},{"date":"2025-03-28","current":-7.687386,"twenty":-19.585275,"median":-11.1295,"eighty":-7.412018,"marketCap":33370944},{"date":"2025-04-02","current":-7.314981,"twenty":-19.585275,"median":-11.033886,"eighty":-7.373772,"marketCap":33370944}],"updateTime":1743704933575}}}